Author

F. Lucien

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 3 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1

Frequent Co-Authors

H. Dong· 2 shared J. B. Hirdler· 2 shared J. K. Gicobi· 2 shared M. A. Hsu· 2 shared A. Feven· 1 shared A. Revzin· 1 shared A. S. Mansfield· 1 shared B. C. Leibovich· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

H. Dong

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

The anti-B7-H3 blocking antibody MJ18 does not recognize B7-H3 in murine tumor models

T. Nammor, J. Frizzell, R. Lavoie, F. Lucien

This study shows that the anti-B7-H3 antibody MJ18 does not bind B7-H3 but instead binds FcγRIIB and fails to induce tumor regression in murine models.

bioRxiv · Nov 15, 2023 · PreprintCancer Biology

Nanoprojectile Secondary Ion Mass Spectrometry Enables Multiplexed Analysis of Individual Hepatic Extracellular Vesicles

S. Lee, D. S. Verkhoturov, M. J. Eller, S. V. Verkhoturov, M. Shaw, K. Gwon, Y. Kim, F. Lucien, H. Malhi, A. Revzin, E. A. Schweikert

This study uses NP-SIMS to analyze single hepatic extracellular vesicles, distinguishing between normal and cancerous EVs based on surface marker expression.

bioRxiv · Aug 21, 2023Bioengineering

Resilient CD8+ T cells maintain a high cytotoxic capacity by balancing ROS via ME1 upregulation

J. K. Gicobi, Z. Mao, G. DeFranco, Y. Li, X. Liu, J. B. Hirdler, V. V. Vianzon, E. R. Dellacecca, M. A. Hsu, W. Barham, Y. H. Kim, A. Feven, W. S. Harmsen, Y. Yan, R. S. Dronca, , H. Dong

This paper identifies CX3CR1+ CD8+ T cells with low mitochondrial membrane potential as functionally resilient, showing high cytotoxicity and reduced ROS through ME1 upregulation, which enhances their anti-tumor activity.

bioRxiv · Nov 25, 2022 · PreprintImmunology

Discovery of a novel monoclonal PD-L1 antibody H1A that promotes T-cell mediated tumor killing activity in renal cell carcinoma

Z. An, M. A. Hsu, J. K. Gicobi, T. Xu, S. M. Harrington, H. Zhang, K. D. Pavelko, J. B. Hirdler, C. Lohse, R. Nabavizadeh, R. R. Pessoa, V. Sharma, R. H. Thompson, B. C. Leibovich, H. Dong, F. Lucien

This study identifies a novel monoclonal PD-L1 antibody H1A that enhances T-cell mediated tumor killing in renal cell carcinoma compared to existing PD-1/PD-L1 inhibitors.

bioRxiv · Sep 10, 2022 · PreprintImmunology